Sarepta Therapeutics (SRPT) Assets Average (2011 - 2026)

Sarepta Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $3.3 billion for Q1 2026.

• On a quarterly basis, Assets Average fell 12.11% year-over-year to $3.3 billion in Q1 2026; TTM through Mar 2026 was $3.3 billion, a 12.11% decrease from a year earlier, with the FY2025 full-year figure at $3.7 billion, up 1.18% from the prior year.
• Assets Average slipped to $3.3 billion in Q1 2026 per SRPT's latest filing, from $3.4 billion in the prior quarter.
• Across five years, Assets Average topped out at $3.8 billion in Q4 2024 and bottomed at $3.0 billion in Q2 2022.
• The 5-year median for Assets Average is $3.2 billion (2024), against an average of $3.3 billion.
• Across the five-year window, Assets Average grew 18.65% in 2024 and dropped 12.11% in 2026, its largest moves.
• Year by year, Assets Average stood at $3.1 billion in 2022, then rose by 1.43% to $3.2 billion in 2023, then rose by 18.65% to $3.8 billion in 2024, then decreased by 9.52% to $3.4 billion in 2025, then declined by 4.6% to $3.3 billion in 2026.
• Per Business Quant, the three latest SRPT Assets Average figures stand at $3.3 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.6 billion (Q3 2025).